AVDL - Avadel Pharmaceuticals PLC Stock Price, Fair Value and News

17.32USD-0.01 (-0.06%)Market Closed

Market Summary

USD17.32-0.01

Market Closed

-0.06%

AVDL Stock Price

View Fullscreen

AVDL RSI Chart

AVDL Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-9.79

Price/Sales (Trailing)

55.91

EV/EBITDA

-10.31

Price/Free Cashflow

-12.21

AVDL Price/Sales (Trailing)

AVDL Profitability

EBT Margin

-572.99%

Return on Equity

-182.67%

Return on Assets

-97.32%

Free Cashflow Yield

-8.19%

AVDL Fundamentals

AVDL Revenue

Revenue (TTM)

28.1M

Rev. Growth (Yr)

5.9K%

Rev. Growth (Qtr)

175.97%

AVDL Earnings

Earnings (TTM)

-160.3M

Earnings Growth (Yr)

-4.87%

Earnings Growth (Qtr)

20.64%

Breaking Down AVDL Revenue

Last 7 days

8.4%

Last 30 days

4.6%

Last 90 days

15.7%

Trailing 12 Months

75.4%

How does AVDL drawdown profile look like?

AVDL Financial Health

Current Ratio

3.64

AVDL Investor Care

Shares Dilution (1Y)

45.37%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.4M	17.6M	22.8M	28.1M
2022	0	1.9M	1.9M	7.2M
2021	17.3M	12.3M	7.3M	2.3M
2020	55.0M	47.6M	33.3M	22.3M
2019	86.4M	74.7M	69.1M	59.2M
2018	154.4M	136.6M	116.7M	103.3M
2017	166.2M	175.1M	182.7M	173.6M
2016	176.6M	166.2M	150.9M	149.9M
2015	54.5M	94.0M	133.6M	173.1M
2014	6.9M	9.6M	12.3M	15.0M
2013	6.7M	5.9M	5.0M	4.2M
2012	26.3M	20.1M	13.8M	7.5M
2011	35.6M	34.1M	0	32.6M
2010	0	0	0	37.1M
2009	0	0	0	42.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avadel Pharmaceuticals PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 16, 2024	mchugh thomas s	bought	29,000	14.5	2,000	chief financial officer
Dec 28, 2023	mccamish mark anthony	sold	-1,089,750	14.53	-75,000	-
Aug 14, 2023	mchugh thomas s	bought	28,900	14.45	2,000	chief financial officer
Aug 11, 2023	mccamish mark anthony	sold	-432,614	14.9306	-28,975	-
Aug 10, 2023	divis gregory j	bought	131,997	13.1997	10,000	chief executive officer
Aug 10, 2023	glass geoffrey michael	bought	187,600	13.4	14,000	-
May 18, 2023	ende eric j	bought	181,100	13.9308	13,000	-
May 09, 2023	palczuk linda	bought	36,900	14.76	2,500	-
Dec 23, 2022	palczuk linda	bought	14,405	7.2025	2,000	-
Nov 29, 2022	mchugh thomas s	bought	39,000	7.8	5,000	chief financial officer

Which funds bought or sold AVDL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Blue Zone Wealth Advisors, LLC	added	5.88	63,980	304,020	0.10%
Apr 18, 2024	Claro Advisors LLC	new	-	171,687	171,687	0.03%
Apr 16, 2024	Edge Wealth Management LLC	reduced	-73.33	-1,442,400	675,600	0.14%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	554	3,378	-%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	unchanged	-	1,385	8,445	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	1,247	7,601	-%
Apr 10, 2024	Banque Cantonale Vaudoise	unchanged	-	3,000	17,000	-%
Apr 05, 2024	CWM, LLC	new	-	2,000	2,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	239	13,467	17,971	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	169	10,037,000	13,760,000	-%

Are Funds Buying or Selling AVDL?

Are funds buying AVDL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVDL

No. of Funds

Unveiling Avadel Pharmaceuticals PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	9.99%	9,196,186	SC 13G/A
Feb 13, 2024	polar capital holdings plc	7.51%	6,751,782	SC 13G
Feb 13, 2024	janus henderson group plc	12.4%	11,125,330	SC 13G/A
Feb 13, 2024	gendell jeffrey l	3.94%	3,539,782	SC 13G/A
Feb 12, 2024	kotler kevin	4.1%	3,716,242	SC 13G/A
Aug 10, 2023	janus henderson group plc	12.3%	9,443,642	SC 13G
Mar 09, 2023	kotler kevin	5.1%	3,122,100	SC 13G
Feb 14, 2023	gendell jeffrey l	5.33%	3,294,817	SC 13G/A
Feb 14, 2023	rtw investments, lp	9.3%	5,741,939	SC 13G/A
Feb 14, 2023	vivo opportunity, llc	3.6%	2,251,663	SC 13G/A

Recent SEC filings of Avadel Pharmaceuticals PLC

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	8-A12B	8-A12B
Mar 04, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Feb 29, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Avadel Pharmaceuticals PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	359.2B	85.2B	-5.03%	-9.57%	10.22	4.22	6.46%	95.94%
MRK	321.6B	60.1B	1.61%	10.23%	881.01	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-6.17%	-34.78%	-106.84	3.19	42.59%	-114.62%
AMGN	145.8B	28.2B	-1.51%	10.46%	21.7	5.17	7.09%	2.52%
GILD	83.4B	27.1B	-9.77%	-21.18%	14.72	3.07	-0.60%	23.36%
TEVA	14.4B	15.8B	-4.60%	54.01%	-25.04	0.91	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-1.63%	-14.16%	-328.65	0.9	4.58%	90.97%
ALKS	4.0B	1.7B	-13.93%	-17.76%	11.3	2.42	49.61%	324.78%
BHC	3.1B	8.8B	-9.38%	13.00%	-5.22	0.35	7.79%	-163.11%
AMPH	1.9B	644.4M	-9.13%	-7.04%	14.05	3	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-12.63%	-26.38%	-3.8	1.8	24.65%	80.36%
TXMD	21.7M	1.3M	-20.43%	-49.32%	-2.11	16.65	-98.14%	-109.18%
ACRX	16.0M	-	-10.09%	36.11%	-0.87	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	-34.48%	-94.22%	-0.18	0.14	80.00%	43.08%
ACOR	546.5K	117.6M	-96.48%	-95.45%	0	0	-0.79%	-283.60%

Avadel Pharmaceuticals PLC News

Latest updates

Avadel Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	176.0%	19,356,500	7,014,000	1,496,000	193,000	320,500	448,000	192,000	812,000	489,000	432,000	216,000	-	-	10,091,000	12,243,000	10,995,000	14,229,000	17,554,000	16,437,000	20,920,000	19,826,000
Gross Profit	172.0%	18,760,000	6,897,000	1,460,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-100.0%	-	42,007,000	51,001,000	28,298,000	23,038,000	16,960,000	29,937,000	23,136,000	25,663,000	21,936,000	14,811,000	14,260,000	13,697,000	-30,178,000	18,740,000	18,342,000	18,376,000	22,005,000	24,604,000	96,341,000	33,921,000
S&GA Expenses	5.5%	41,301,000	39,158,000	46,778,000	24,468,000	16,981,000	14,096,000	21,804,000	21,026,000	21,283,000	15,174,000	11,012,000	8,974,000	8,423,000	7,095,000	7,913,000	7,663,000	5,316,000	6,758,000	10,446,000	23,200,000	24,829,000
R&D Expenses	-17.2%	2,359,000	2,849,000	4,223,000	3,830,000	6,235,000	2,933,000	4,541,000	2,110,000	4,380,000	6,762,000	3,852,000	5,286,000	5,569,000	4,057,000	5,530,000	7,757,000	7,539,000	10,292,000	7,329,000	6,086,000	11,402,000
EBITDA Margin	16.9%	-5.31	-6.40	-54.89	-41.25	-41.66	-41.13	-44.91	-35.16	-9.61	-4.76	0.14	0.43	-	-	-	-	-	-	-	-	-
Interest Expenses	19.0%	2,354,000	1,978,000	2,295,000	3,259,000	3,255,000	3,564,000	3,506,000	4,154,000	1,929,000	1,930,000	1,929,000	3,308,000	3,259,000	3,237,000	3,190,000	3,190,000	3,125,000	3,106,000	3,062,000	3,045,000	3,000,000
Income Taxes	-212.4%	-100,000	89,000	90,000	-580,000	85,000	70,000	30,193,000	-4,343,000	-5,101,000	-3,765,000	-2,607,000	-2,852,000	-5,040,000	5,292,000	-9,510,000	-8,997,000	2,234,000	1,781,000	-374,000	-14,533,000	-691,000
Earnings Before Taxes	20.2%	-28,886,000	-36,185,000	-64,342,000	-31,364,000	-27,365,000	-20,076,000	-33,251,000	-26,644,000	-27,103,000	-23,346,000	-16,052,000	-14,130,000	-16,743,000	36,166,000	-10,375,000	-11,736,000	-6,630,000	-6,824,000	-13,392,000	-78,392,000	-16,462,000
EBT Margin	17.8%	-5.73	-6.97	-61.10	-47.83	-47.56	-47.25	-50.25	-39.75	-10.98	-5.70	-0.62	-0.23	-	-	-	-	-	-	-	-	-
Net Income	20.6%	-28,786,000	-36,274,000	-64,432,000	-30,784,000	-27,450,000	-20,146,000	-63,444,000	-22,301,000	-22,002,000	-19,581,000	-13,445,000	-11,278,000	-11,703,000	30,874,000	-865,000	-2,739,000	-8,864,000	-8,605,000	-13,018,000	-63,859,000	-15,771,000
Net Income Margin	17.9%	-5.71	-6.96	-60.95	-60.53	-58.67	-56.47	-57.26	-33.00	-9.03	-4.54	-0.32	0.31	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-28,029,000	-	-32,023,000	-30,233,000	-15,366,000	-7,519,000	-14,090,000	-22,506,000	-21,238,000	-10,153,000	-23,439,000	-19,190,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.9%	165	203	201	141	133	146	158	221	247	264	283	293	312	328	341	208	151	156	166	174	190
Current Assets	-22.1%	134	172	171	109	101	113	126	161	192	206	231	242	263	282	277	131	82.00	89.00	97.00	102	125
Cash Equivalents	-39.8%	31.00	52.00	50.00	83.00	74.00	61.00	54.00	61.00	51.00	58.00	67.00	59.00	72.00	83.00	102	74.00	10.00	13.00	17.00	10.00	9.00
Inventory	96.4%	10.00	5.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	2.00	3.00	4.00	5.00
Net PPE	-9.7%	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	2.00	2.00
Goodwill	0%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	18.00	18.00	18.00	18.00	18.00	18.00
Liabilities	-17.2%	77.00	93.00	58.00	179	154	158	161	166	169	165	164	156	149	156	159	176	181	183	183	183	188
Current Liabilities	-31.8%	37.00	54.00	52.00	79.00	56.00	42.00	46.00	44.00	21.00	18.00	16.00	9.00	15.00	23.00	27.00	32.00	36.00	32.00	34.00	31.00	38.00
Long Term Debt	-	-	-	-	93.00	92.00	110	108	117	142	142	142	141	128	127	125	123	122	120	119	117	116
LT Debt, Current	-100.0%	-	21.00	21.00	21.00	38.00	26.00	26.00	26.00	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
LT Debt, Non Current	-	-	-	-	93.00	92.00	110	108	117	142	142	142	141	128	127	125	123	122	120	119	117	116
Shareholder's Equity	-20.3%	88.00	110	143	-	-21.14	-	-	55.00	78.00	99.00	119	137	162	171	182	32.00	-	-	-	-	3.00
Retained Earnings	-4.0%	-745	-716	-680	-616	-585	-557	-537	-474	-447	-425	-403	-383	-384	-372	-361	-392	-391	-388	-379	-371	-357
Additional Paid-In Capital	0.4%	855	852	849	603	590	573	560	554	549	547	544	542	567	565	615	497	434	434	434	434	434
Shares Outstanding	0.5%	90.00	89.00	89.00	64.00	63.00	59.00	59.00	59.00	59.00	59.00	58.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,459	-	-	-	142	-	-	-	390	-	-	-	467	-	-	-	98.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	26.7%	-28,029	-38,226	-32,023	-30,233	-15,366	-6,803	-14,090	-34,045	-22,506	-21,238	-10,153	-23,413	-19,125	-10,192	-7,781	-11,636	-8,253	-7,419	-1,447	-21,206	-24,526
Share Based Compensation	12.5%	3,518	3,127	7,644	1,522	1,927	1,923	658	2,505	2,784	2,359	2,001	1,728	1,294	194	769	742	342	-229	55.00	351	662
Cashflow From Investing	184.4%	27,928	9,821	-92,908	5,066	22,875	2,524	12,048	42,251	15,320	12,294	18,124	11,191	7,241	-9,300	-80,888	13,226	5,170	3,217	8,946	21,390	16,207
Cashflow From Financing	-169.3%	-21,111	30,460	91,544	34,442	6,622	10,715	-4,803	2,009	-	114	-	149	183	-16.00	117,306	62,210	-41.00	-41.00	-37.00	92.00	-76.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

AVDL Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (160,276)	$ (137,464)	$ (77,329)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	331	(597)	(1,228)
Net other comprehensive income (loss), net of income tax benefit of $0, $0, and $214, respectively	2,843	(1,804)	(1,661)
Total other comprehensive income (loss), net of tax	3,174	(2,401)	(2,889)
Total comprehensive loss	$ (157,102)	$ (139,865)	$ (80,218)

AVDL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 31,167	$ 73,981
Marketable securities	73,944	22,518
Accounts receivable, net	12,103	0
Inventories	10,380	0
Research and development tax credit receivable	1,322	2,248
Prepaid expenses and other current assets	5,286	2,096
Total current assets	134,202	100,843
Property and equipment, net	585	839
Operating lease right-of-use assets	2,591	1,713
Goodwill	16,836	16,836
Research and development tax credit receivable	332	1,232
Other non-current assets	10,152	11,322
Total assets	164,698	132,785
Current liabilities:
Current portion of long-term debt	0	37,668
Current portion of operating lease liability	934	960
Accounts payable	11,433	7,890
Accrued expenses	24,227	7,334
Other current liabilities	261	1,941
Total current liabilities	36,855	55,793
Long-term debt	0	91,614
Long-term operating lease liability	1,690	780
Royalty financing obligation	32,760	0
Other non-current liabilities	5,654	5,743
Total liabilities	76,959	153,930
Shareholders’ equity (deficit):
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; 5,194 issued and outstanding at December 31, 2023 and 488 issued and outstanding at December 31, 2022	52	5
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 89,825 issued and outstanding at December 31, 2023 and 62,878 issued and outstanding at December 31, 2022	898	628
Additional paid-in capital	855,452	589,783
Accumulated deficit	(745,496)	(585,220)
Accumulated other comprehensive loss	(23,167)	(26,341)
Total shareholders’ equity (deficit)	87,739	(21,145)
Total liabilities and shareholders’ equity (deficit)	$ 164,698	$ 132,785

About Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

CEO	Mr. Gregory J. Divis Jr.
WEBSITE	avadel.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	41

Avadel Pharmaceuticals PLC Frequently Asked Questions

What is the ticker symbol for Avadel Pharmaceuticals PLC? What does AVDL stand for in stocks?

AVDL is the stock ticker symbol of Avadel Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avadel Pharmaceuticals PLC (AVDL)?

As of Fri Apr 19 2024, market cap of Avadel Pharmaceuticals PLC is 1.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers. The fair value of Avadel Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avadel Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVDL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avadel Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether AVDL is over valued or under valued. Whether Avadel Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Avadel Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVDL.

What is Avadel Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, AVDL's PE ratio (Price to Earnings) is -9.79 and Price to Sales (PS) ratio is 55.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVDL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avadel Pharmaceuticals PLC's stock?

In the past 10 years, Avadel Pharmaceuticals PLC has provided 0.039 (multiply by 100 for percentage) rate of return.